SEC Form 4 · accession 0001567619-19-005004
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqueline Studer
Officer — CVP, Gen. Counsel & Secretary
Period of report
Feb 15, 2019
Accepted (ET)
Feb 20, 2019 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2019 | M | 2,866 | $79.54 | A | 8,648 | D | |
| Common StockF1 | Feb 15, 2019 | S | 2,866 | $207.5352 | D | 5,762 | D | |
| Common Stock | Feb 15, 2019 | M | 100 | $79.54 | A | 5,862 | D | |
| Common Stock | Feb 15, 2019 | S | 100 | $207.80 | D | 5,762 | D | |
| Common Stock | Feb 15, 2019 | M | 4,700 | $67.85 | A | 10,462 | D | |
| Common StockF2 | Feb 15, 2019 | S | 4,700 | $208.5389 | D | 5,762 | D | |
| Common Stock | Feb 15, 2019 | M | 1 | $67.85 | A | 5,763 | D | |
| Common Stock | Feb 15, 2019 | S | 1 | $208.90 | D | 5,762 | D | |
| Common Stock | Feb 15, 2019 | M | 2,219 | $141.60 | A | 7,981 | D | |
| Common StockF3 | Feb 15, 2019 | S | 2,219 | $208.9523 | D | 5,762 | D | |
| Common Stock | Feb 15, 2019 | M | 1,714 | $178.26 | A | 7,476 | D | |
| Common StockF4 | Feb 15, 2019 | S | 1,714 | $209.1794 | D | 5,762 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F10,F5 | $79.54 | Feb 15, 2019 | M | 2,866 | D | — | Feb 13, 2025 | Common Stock | 2,866 | 2,866 | D |
| Incentive Stock Option (right-to-buy)F10,F6 | $79.54 | Feb 15, 2019 | M | 100 | D | — | Feb 13, 2025 | Common Stock | 100 | 1,864 | D |
| Non-Qualified Stock Option (right-to-buy)F10,F7 | $67.85 | Feb 15, 2019 | M | 4,700 | D | — | Feb 13, 2026 | Common Stock | 4,700 | 7,927 | D |
| Incentive Stock Option (right-to-buy)F10,F7 | $67.85 | Feb 15, 2019 | M | 1 | D | — | Feb 13, 2026 | Common Stock | 1 | 1,474 | D |
| Non-Qualified Stock Option (right-to-buy)F10,F8 | $141.60 | Feb 15, 2019 | M | 2,219 | D | — | Feb 13, 2027 | Common Stock | 2,219 | 5,948 | D |
| Non-Qualified Stock Option (right-to-buy)F10,F9 | $178.26 | Feb 15, 2019 | M | 1,714 | D | — | Feb 13, 2028 | Common Stock | 1,714 | 6,293 | D |
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $207.08 to a high of $208.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F10Not applicable.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $207.81 to a high of $208.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $208.91 to a high of $209.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sales price of the shares sold ranging from a low of $209.10 to a high of $209.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F6Grant of option to buy 3,140 shares of Issuer common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F7Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017.
- F8Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2018.
- F9Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2019.